Brandon Folkes, an analyst from Rodman & Renshaw, has initiated a new Buy rating on Cardiol Therapeutics (CRDL).
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight the potential of Cardiol Therapeutics. The company is at the forefront of developing innovative therapies for heart disease, focusing on anti-inflammatory and anti-fibrotic treatments. Their lead product, CardiolRx, is a high-purity cannabidiol oral solution that stands out due to its ability to modulate inflammasome pathway activation without THC, making it suitable for a wide range of cardiac patients.
Cardiol Therapeutics is advancing CardiolRx through key programs targeting recurrent pericarditis and acute myocarditis, with the potential to unlock significant value. The upcoming data release from the Phase II ARCHER trial for acute myocarditis could attract strategic partnerships. Additionally, the development of CRD-38 for heart failure presents a substantial market opportunity, given the lack of approved drugs targeting inflammatory mechanisms in heart failure. The potential revenue from these programs, along with the ongoing MAVERIC trial for recurrent pericarditis, supports a favorable risk-reward profile for investors in CRDL shares.
In another report released on May 15, Canaccord Genuity also reiterated a Buy rating on the stock with a $8.00 price target.